Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obalon Therapeutics Inc    OBLN

OBALON THERAPEUTICS INC (OBLN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
7.97(c) 7.87(c) 7.78(c) 8(c) 8.03(c) Last
50 990 48 579 38 920 32 135 61 551 Volume
-0.87% -1.25% -1.14% +2.83% +0.37% Change
More quotes
Financials ($)
Sales 2017 9,54 M
EBIT 2017 -32,3 M
Net income 2017 -31,2 M
Finance 2017 29,0 M
Yield 2017 -
Sales 2018 23,1 M
EBIT 2018 -29,1 M
Net income 2018 -28,6 M
Finance 2018 5,73 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 11,6x
EV / Sales2018 5,81x
Capitalization 140 M
More Financials
Company
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss.Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then... 
More about the company
Surperformance© ratings of Obalon Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OBALON THERAPEUTICS INC
11/06 Obalon Announces Upcoming Conference Presentations
11/03 OBALON THERAPEUTICS, INC. (NASDAQ : OBLN) Files An 8-K Results of Operations and..
11/03 OBALON THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
11/03 Obalon Announces Third Quarter 2017 Financial Results
11/03 OBALON THERAPEUTICS INC : Obalon Therapeutics, Inc. to Host Earnings Call
11/02 Obalon Therapeutics, Inc. and Sono Bello Announce Agreement to Offer Novel We..
10/26 OBALON SCHEDULES THIRD QUARTER 2017 : 30 a.m. Eastern Time
09/11 OBALON THERAPEUTICS, INC. (NASDAQ : OBLN) Files An 8-K Departure of Directors or..
09/08 OBALON THERAPEUTICS INC : Financial Statements and Exhibits (form 8-K)
09/07 Kelly Huang, Ph.D., Joins Obalon Therapeutics, Inc. Executive Team
More news
Sector news : Medical Devices & Implants
11/13 Poor earnings updates keep European shares at seven-week low
11/13 SONOVA : misses sales, profit forecasts as U.S. overhaul bites
11/12 FISHER & PAYKEL HEALTHCARE : & Paykel says UK court rules rival Resmed's patent ..
11/03 ESSILOR INTERNATIONAL : EU regulators suspend Luxottica, Essilor probe, await da..
11/03DJESSILOR INTERNATIONAL : EU Regulator Has Suspended Essilor, Luxottica Probe -Reu..
More sector news : Medical Devices & Implants
News from SeekingAlpha
11/06 Analyst action - healthcare
11/03 Obalon Therapeutics' (OBLN) CEO Andrew Rasdal on Q3 2017 Results - Earnings C..
11/03 Obalon Therapeutics reports Q3 results
11/03 Obalon Therapeutics misses by $0.10, misses on revenue
11/02 Equity offering registration roundup - healthcare
Chart OBALON THERAPEUTICS INC
Duration : Period :
Obalon Therapeutics Inc Technical Analysis Chart | OBLN | US67424L1008 | 4-Traders
Technical analysis trends OBALON THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 14,0 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Andrew P. Rasdal President, Chief Executive Officer & Director
Kim P. Kamdar Chairman
Kelly Huang Chief Operating Officer
William John Plovanic Chief Financial Officer & Secretary
Mark Brister Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
OBALON THERAPEUTICS INC-9.27%140
STRYKER CORPORATION29.71%58 157
SMITH & NEPHEW8.68%15 313
WRIGHT MEDICAL GROUP NV7.92%2 604
JAPAN LIFELINE CO., LTD.122.13%2 089
GLAUKOS CORP-22.89%914